Appili Therapeutics

Appili Therapeutics company information, Employees & Contact Information

Appili Therapeutics is an infectious disease biopharmaceutical company that is purposefully built, portfolio-driven, and people-focused to fulfill its mission of solving life-threatening infections. By systematically identifying urgent infections with unmet needs, Appili’s goal is to strategically develop a pipeline of novel therapies to prevent deaths and improve lives.

Company Details

Employees
20
Founded
-
Address
Halifax, Nova Scotia B3h 0a8, Ca
Phone
(902)442-4655
Email
in****@****ics.com
Industry
Biotechnology Research
NAICS
Research and Development in Biotechnology (except Nanobiotechnology)
HQ
Halifax, Nova Scotia
Looking for a particular Appili Therapeutics employee's phone or email?

Appili Therapeutics Questions

News

Appili Therapeutics (TSX: APLI) to attend BARDA event; $40M NIAID award, $66M funding - Stock Titan

Appili Therapeutics (TSX: APLI) to attend BARDA event; $40M NIAID award, $66M funding Stock Titan

Appili Therapeutics Provides Update on Arrangement with Aditxt, Inc. - Yahoo Finance

Appili Therapeutics Provides Update on Arrangement with Aditxt, Inc. Yahoo Finance

Appili Therapeutics to Attend BARDA Innovation Symposium 2025 - Lelezard

Appili Therapeutics to Attend BARDA Innovation Symposium 2025 Lelezard

Appili Therapeutics Announces Formal Termination of Arrangement Agreement with Aditxt Inc. - Yahoo Finance

Appili Therapeutics Announces Formal Termination of Arrangement Agreement with Aditxt Inc. Yahoo Finance

First-Ever Human Fungal Vaccine: Appili, Vitalex Win $40M to Combat Deadly Candida Infections Killing 3.8M Annually - Stock Titan

First-Ever Human Fungal Vaccine: Appili, Vitalex Win $40M to Combat Deadly Candida Infections Killing 3.8M Annually Stock Titan

Aditxt agrees to acquire Appili Therapeutics - Pharmaceutical Technology

Aditxt agrees to acquire Appili Therapeutics Pharmaceutical Technology

Appili Therapeutics – Press Release Correction - FinancialContent

Appili Therapeutics – Press Release Correction FinancialContent

Considerations for prevention of and emergency response to tularemia outbreaks in Ukraine: vaccine involvement - Frontiers

Considerations for prevention of and emergency response to tularemia outbreaks in Ukraine: vaccine involvement Frontiers

Appili Therapeutics Secures Shareholder Approval for Strategic Initiatives - TipRanks

Appili Therapeutics Secures Shareholder Approval for Strategic Initiatives TipRanks

Appili Therapeutics and its Partner Vitalex Biosciences Awarded Contract from NIAID Valued at up to US$40 Million to Develop Fungal Vaccine VXV-01 - The Manila Times

Appili Therapeutics and its Partner Vitalex Biosciences Awarded Contract from NIAID Valued at up to US$40 Million to Develop Fungal Vaccine VXV-01 The Manila Times

Reformulated Metronidazole Granted Orphan Drug for CDI in Children - Medical Professionals Reference

Reformulated Metronidazole Granted Orphan Drug for CDI in Children Medical Professionals Reference

Appili Therapeutics Reports Financial and Operational Results for Second Quarter of Fiscal Year 2024 - FinancialContent

Appili Therapeutics Reports Financial and Operational Results for Second Quarter of Fiscal Year 2024 FinancialContent

Appili Therapeutics Secures $40 Million Contract for Fungal Vaccine Development - TipRanks

Appili Therapeutics Secures $40 Million Contract for Fungal Vaccine Development TipRanks

Aditxt Secures Overwhelming Shareholder Approval for Appili Therapeutics Acquisition - Stock Titan

Aditxt Secures Overwhelming Shareholder Approval for Appili Therapeutics Acquisition Stock Titan

Appili Therapeutics Announces Results of Annual Meeting of Shareholders and Provides Corporate Update - FinancialContent

Appili Therapeutics Announces Results of Annual Meeting of Shareholders and Provides Corporate Update FinancialContent

Appili Therapeutics to Present Progress on Tularemia Biodefense Vaccine at NATO CBRN Conference - The Manila Times

Appili Therapeutics to Present Progress on Tularemia Biodefense Vaccine at NATO CBRN Conference The Manila Times

Appili Therapeutics to Present at the 2023 Bloom Burton & Co. Healthcare Investor Conference - FinancialContent

Appili Therapeutics to Present at the 2023 Bloom Burton & Co. Healthcare Investor Conference FinancialContent

Appili Therapeutics Announces Issuance of Patent for ATI-1701 Biodefense Vaccine Candidate to Protect Against Tularemia and Provides Update on Bridge Loan - FinancialContent

Appili Therapeutics Announces Issuance of Patent for ATI-1701 Biodefense Vaccine Candidate to Protect Against Tularemia and Provides Update on Bridge Loan FinancialContent

Appili Therapeutics Presents at the 10th International Tularemia Conference - FinancialContent

Appili Therapeutics Presents at the 10th International Tularemia Conference FinancialContent

Top Appili Therapeutics Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant